ShadiaIJalalMD

Oncology • Indianapolis, IN

Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Associate Professor of Medicine, Indiana University School of Medicinet

Join to view full profile

Dr. Jalal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Jalal's full profile

Already have an account?

Office
535 Barnhill Dr
Indianapolis, IN 46202
Phone+1 317-274-5500
Is this information wrong?

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
Indiana University School of MedicineResidency, Internal Medicine, 2003 - 2006
University of Jordan Faculty of MedicineClass of 2002

Certifications & Licensure

IN State Medical License 2009 - 2025

Clinical Trials

Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors Start of enrollment: 2010 May 14
Completed
Phase 1
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2010 Sep 21
Active, not recruiting
Phase 2
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2, Phase 3
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
Completed
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Circulating Tumor Cells (CTC) in Lung Cancer Start of enrollment: 2017 Oct 19
Recruiting
A Study of Durvalumab (MEDI4736) in Esophageal Cancer Start of enrollment: 2016 Apr 27
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2018 Nov 02
Completed
Not Applicable
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma Start of enrollment: 2019 Jul 09
Active, not recruiting
Phase 2
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer Start of enrollment: 2019 Jun 06
Completed
Phase 2
Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting for Actively Smoking Family Members Start of enrollment: 2021 Sep 13
Terminated
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) Start of enrollment: 2021 Sep 15
Terminated
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Comparative oncology chemosensitivity assay for personalized medicine using low-coherence digital holography of dynamic light scattering from cancer biopsies.
Hua, Z., Li, Z., Lim, D., Ajrouch, A., Childress, M., Turek, J., Nolte, D., Karkash, A., Jalal, S.> ;Scientific Reports. 2024 Feb 8
1 citations
Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.
Ryan D Gentzler, Nisha A Mohindra, Shadia I Jalal, Karen L Reckamp, Richard D Hall, Nasser H Hanna, Young Kwang Chae, Marianna Koczywas, Irene B Helenowski, Jyoti D Patel> ;The Oncologist. 2024 Jan 5
A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell ...
Hirva Mamdani, Ryan Gentzler, Maitri Kalra, Susan Perkins, Sandra Althouse, Shadia I Jalal, Wei, C.> ;Clinical Lung Cancer. 2023 Jun 1
1 citations
LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
Ting Zhao, Sheng Liu, Nasser H Hanna, Shadia Jalal, Xinchun Ding, Jun Wan, Cong Yan, Hong Du> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
2 citations
Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.
Ahmed Bilal Khalid, Gerardo Calderon, Shadia I Jalal, Greg A Durm> ;Journal of the National Comprehensive Cancer Network. 2022 Dec 1
1 citations
Relations of perceived injustice to psycho-spiritual outcomes in advanced lung and prostate cancer: Examining the role of acceptance and meaning making.
Ekin Secinti, Wei Wu, Ellen F Krueger, Adam T Hirsh, Alexia M Torke, Nasser H Hanna, Nabil Adra, Gregory A Durm, Lawrence Einhorn, Roberto Pili, Shadia I Jalal, Cather...> ;Psycho-Oncology. 2022 Dec 1
Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program.
Shadia I Jalal, Aixia Guo, Sara Ahmed, Michael J Kelley> ;Seminars in Oncology. 2022 Jul 19
9 citations
Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors.
Andrea M Chambers, Kyle B Lupo, Jiao Wang, Jingming Cao, Sagar Utturkar, Nadia Lanman, Victor Bernal-Crespo, Shadia Jalal, Sharon R Pine, Sandra Torregrosa-Allen, Benn...> ;Elife. 2022 Jul 11
15 citations
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako...> ;Clinical Cancer Research. 2022 May 13
25 citations
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.
Kathryn F Mileham, Caroline Schenkel, Suanna S Bruinooge, Janet Freeman-Daily, Upal Basu Roy, Amy Moore, Robert A Smith, Elizabeth Garrett-Mayer, Lauren Rosenthal, Edw...> ;Cancer Medicine. 2022 Jan 1
89 citations
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Hirva Mamdani, Sandro Matosevic, Ahmed Bilal Khalid, Gregory Durm, Shadia I Jalal> ;Frontiers in Immunology. 2022 Jan 1
5 citations
Targeting Replication Protein A for Cancer Therapy.
Pamela S VanderVere-Carozza, Navnath S Gavande, Shadia I Jalal, Karen E Pollok, Elmira Ekinci, Joshua Heyza, Steve M Patrick, Andi Masters, John J Turchi, Katherine S ...> ;Frontiers in Oncology. 2022 Jan 1
1 citations
Role of surgery following neoadjuvant chemoradiation in patients with lymph node positive locally advanced esophageal adenocarcinoma: a national cancer database analysis
Hirva Mamdani, Thomas J. Birdas, Shadia I. Jalal> ;Journal of Gastrointestinal Oncology. 2021 Oct 1
14 citations
A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Re...
Hirva Mamdani, Bryan J. Schneider, Susan M. Perkins, Heather Burney, Pashtoon Murtaza Kasi, Laith Abushahin, Thomas J. Birdas, Kenneth A. Kesler, Tracy Watkins, Sunil ...> ;Frontiers in Oncology. 2021 Sep 17
11 citations
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Nuria Kotecki, P. Vuagnat, Bert H. O'Neil, Shadia I. Jalal, Sylvie Rottey, Hans Prenen, Karim A. Benhadji, Meng Xia, Anna M. Szpurka, Abhijoy Saha, Johan Wallin, Subha...> ;Journal of Immunotherapy. 2021 Apr 28
3 citations
Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence.
Ryan Nguyen, Laura B. Vater, Lava Timsina, Greg Andrew Durm, Katelin Rupp, Keylee Wright, Miranda H. Spitznagle, Brandy Paul, Shadia I. Jalal, Lisa Carter-Harris, Kare...> ;Plos One. 2021 Apr 16
1 citations
Measurement of patients’ acceptable symptom levels and priorities for symptom improvement in advanced lung cancer
Ellen Krueger, Ekin Secinti, Wei Wu, Nasser H. Hanna, G. Durm, Lawrence H. Einhorn, Shadia I. Jalal, Catherine E. Mosher> ;Supportive Care in Cancer. 2021 Mar 24
1 citations
Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer
Hirva Mamdani, Shadia I. Jalal> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2021 Mar 25
29 citations
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group.
Allison Magnuson, Suanna S. Bruinooge, Harpreet Singh, Keith D. Wilner, Shadia I. Jalal, Stuart M. Lichtman, Paul G. Kluetz, Gary H. Lyman, Heidi D. Klepin, Mark E. Fl...> ;Clinical Cancer Research. 2021 Feb 9
9 citations
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.
Raymond U. Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, Suparna Wedam, Gwynn Ison, Sol Atienza, Peter De Porre, Tithi Biswas, Jamie N. Holloway, David S. Hong, ...> ;Clinical Cancer Research. 2021 Feb 9
76 citations
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
Mark M. Awad, Shirish M. Gadgeel, Hossein Borghaei, Amita Patnaik, James Chih-Hsin Yang, Steven Francis Powell, Ryan D. Gentzler, Renato G. Martins, James P. Stevenson...> ;Journal of Thoracic Oncology. 2021 Jan 1
40 citations
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
Hirva Mamdani, Shadia I. Jalal> ;Frontiers in Cell and Developmental Biology. 2020 Oct 9
78 citations
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier cancer ...
Greg Andrew Durm, Salma K. Jabbour, Sandra Althouse, Ziyue Liu, Ahad Ali Sadiq, Robin Zon, Shadia I. Jalal, Goetz H. Kloecker, Michael J. Williamson, Karen L. Reckamp,...> ;Cancer. 2020 Oct 1
5 citations
Tissue dynamics spectroscopic imaging: functional imaging of heterogeneous cancer tissue.
Zhe Li, Bihe Hu, Guang Li, Sharon E. Fox, Shadia I. Jalal, John J. Turek, J. Quincy Brown, David D. Nolte> ;Journal of Biomedical Optics. 2020 Sep 1
49 citations
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Martin H. Voss, Michael S. Gordon, Monica M. Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla, David Smith, Andrés Cervantes, Igor Puzanov, Roberto Pili, Ding Wang,...> ;British Journal of Cancer. 2020 Sep 11
Join now to see all

Journal Articles

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase 1b Study
Karen Kelly, Montaser Shaheen, Shadia Jalal, Daruka Mahadevan, Clinical Cancer Research

Press Mentions

'No' to Anti-VEGF-Chemo Combo in NSCLC Sans Driver AlterationsFebruary 10th, 2023
Lung Cancer Experts Available from Indiana UniversityNovember 1st, 2017